We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$303M
Cap. Flow %
-7.88%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$487M
2
BPMC
Blueprint Medicines
BPMC
+$13.9M
3
ONC
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 45.68%
2 Consumer Discretionary 28.3%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
$870K 0.02%
150,000
– –
UBX
102
DELISTED
Unity Biotechnology
UBX
$815K 0.02%
5,000
-15,000
-75% -$2.47M
NVLN
103
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$759K 0.02%
256,400
– –
ATYR
104
aTyr Pharma
ATYR
$54.2M
$406K 0.01%
35,714
– –
IMDX
105
Insight Molecular Diagnostics
IMDX
$121M
$375K 0.01%
7,500
– –
AGIO icon
106
CALL
Agios Pharmaceuticals
AGIO
$2B
– –
-50,000
Closed -$4.21M
BLUE
107
CALL
DELISTED
bluebird bio
BLUE
– –
-3,860
Closed -$7.85M
BPMC
108
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-200,000
Closed -$12.7M
DVAX
109
CALL
DELISTED
Dynavax Technologies
DVAX
– –
-250,000
Closed -$3.81M
EXEL icon
110
CALL
Exelixis
EXEL
$12.5B
– –
-500,000
Closed -$10.8M
FBRX icon
111
Forte Biosciences
FBRX
$1.57B
– –
-267
Closed -$934K
CBIO
112
Crescent Biopharma
CBIO
$618M
– –
-2,500
Closed -$4.03M
IBB icon
113
CALL
iShares Biotechnology ETF
IBB
$9.77B
– –
-450,000
Closed -$49.4M
IMUX icon
114
Immunic
IMUX
$226M
– –
-2,500
Closed -$6.85M
KNSA icon
115
Kiniksa Pharmaceuticals
KNSA
$6.07B
– –
-100,000
Closed -$1.74M
SNDX icon
116
Syndax Pharmaceuticals
SNDX
$1.7B
– –
-60,697
Closed -$426K
WVE icon
117
Wave Life Sciences
WVE
$1.02B
– –
-100,000
Closed -$3.83M
ACGN
118
DELISTED
Aceragen Inc
ACGN
– –
-20,241
Closed -$3.63M
CLVS
119
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-100,000
Closed -$4.55M
GBT
120
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-200,000
Closed -$9.04M
XLRN
121
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-100,000
Closed -$4.85M
SNNA
122
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
– –
-99,000
Closed -$1.5M
1 2 3 4
5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $303M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.